Details for Patent: 6,586,476

Title:	Methods for the treatment of nephro-disorders using aminothiol compounds
Abstract:	The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
Inventor(s):	Stogniew; Martin (Blue Bell, PA), Alberts; David S. (Tucson, AZ), Kaplan; Edward H. (Skokie, IL)
Assignee:	MedImmune Oncology, Inc. (Gaithersburg, MD)
Filing Date:	Oct 28, 1999
Application Number:	09/429,290
Claims:	1. A method for treating a nephro-disorders in a human which comprises administering a therapeutically effective amount of one or more aminothiol compounds, or a pharmaceutically acceptable salt thereof, to a human in need of such treatment after the occurrence of said nephro-disorders. 2. The method of claim 1, wherein said nephro-disorder is chemically induced, drug induced, induced by aging, induced by exposure to radiation, induced by diabetes or induced by an unknown etiology. 3. The method of claim 2 wherein said nephro-disorder is induced by diabetes. 4. The method of claim 1, wherein said nephro-disorder is a nephrotoxicity associated with the administration of radiation therapy of one or more therapeutic agent(s). 5. The method of claim 1 wherein said nephro-disorder is characterized by elevations in BUN, serum creatinine, or a decrease in creatinine clearance or sodium magnesium or a combination thereof. 6. The method of claim 4 wherein said therapeutic agent is an antiviral, an antibiotic, an antifungal, a contrast agent or a combination thereof. 7. The method of claim 1 wherein said nephro-disorder is a result of the administration of cisplatin, carboplatin, pactitaxel, docetaxel, vincristine, navelbine, gemcytobin, etoposide, doxorubicin, daunorubicin or a combination thereof. 8. The method of claim 1 wherein said nephro-disorder is a result of the administration of 3'-azido-3'-deoxythymidine (AZT), d4T (stavadine), ddI (didanosine), ddC (zalcitabine), 3TC (lamivudine), gentamicin, tobramicin, kanamicin, amikacin, vancamicin, amphotericin B or a combination thereof. 9. The method of claim 1, wherein said aminothiol compound is administered intravenously, subcutaneously, intramuscularly, intradermally, topically or orally. 10. The method of claim 1 wherein said human is a cancer patient, AIDS patient, diabetic, or hypertensive patient. 11. The method of claim 1 wherein said aminothiol compound is a compound of the formula: or a pharmaceutically acceptable addition salt or hydrate thereof, wherein R.sub.1 is hydrogen, C.sub.5 -C.sub.7 aryl, C.sub.2 -C.sub.7 acyl, or C.sub.1 -C.sub.7 alkyl; R.sub.2 is hydrogen, PO.sub.3 H.sub.2 or R.sub.3 wherein R.sub.3 is R.sub.1 NH(CH.sub.2).sub.n NH(CH.sub.2).sub.m S--; n is an integer from 1 to 10; and m is an integer from 1 to 10. 12. The method of claim 11, wherein said compound is selected from the group consisting of WR-1065, WR-151326, WR-151327, WR-638, WR-3689, WR-2822, WR-2529, WR-77913, WR-255591, WR-2823, WR-255709 and salts or hydrates thereof. 13. The method of claim 1, wherein said aminothiol is amifostine. 14. The method of claim 1, wherein said aminothiol is WR-33278. 15. The method of claim 1, wherein said aminothiol is an active metabolite of WR-2721. 16. The method of claim 1, wherein said aminothiol is a prodrug of an active metabolite of WR-2721. 17. The method of claim 1, wherein said aminothiol is administered one or more days after the occurrence of said nephro-disorders. 18. The method of claim 1, wherein two or more aminothiol compounds are administered. 19. The method of claim 1, wherein the amount administered is from about 10 mg/m.sup.2 to about 2,000 mg/m.sup.2.